



Docket No.: 515-4167

520 Recd PCT/PTO

PCT
10 NOV 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT OPERATION

In re Application of:)
Raffaello Giorgi et al.) Group Art Unit: --
Serial No.: 09/355,210) Examiner: --
Filed: July 23, 1999)
For: MONOCYCLIC COMPOUNDS WITH FOUR BIFUNCTIONAL
RESIDUES HAVING NK-2 ANTAGONIST ACTION

New York, NY 10036
November 8, 1999

Assistant Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

SIR:

The following references are being cited under
the provisions of 37 CFR §1.97:

European Journal of
Pharmacology, 241(1993)
17-25

Discloses tachykinin-
mediated respiratory
effects in conscious
guinea pigs; modulation by
NK₂ and NK₂ receptor
antagonists.


Psychopharmacology (1995)
121:186-191

Discloses anxiolytic-like
activity of GR159897, a
non-peptide NK₂ receptor
antagonist, in rodent and
primate models of anxiety.

I hereby certify that this correspondence is being
deposited with the United States Postal Service
as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, DC 20231

on November 8, 1999



James V. Costigan, Registration No. 25,669

Br. J. Pharmacol. (1991),
104, 355-360

WO 93/21227

Journal of Medicinal
Chemistry, 1994, Vol. 37,
No. 21

J. Med. Chem., 1994, 37,
3630


Discloses pharmacological
specificity of novel,
synthetic, cyclic peptides
as antagonists at
tachykinin receptors.

Discloses tachykinin
antagonist tricyclic
compounds, preparation of
same and pharmaceutical
compositions containing
such compounds.

Discloses influence of
lipophilicity on the
biological activity of
cyclic pseudopeptide NK-2
receptor antagonists.

Discloses antagonistic
activity towards the NK-2
receptor of tachykinins.

Respectfully submitted,



James V. Costigan
Registration No. 25,669

HEDMAN, GIBSON & COSTIGAN, P.C.
1185 Avenue of the Americas
New York, NY 10036-2646
(212) 302-8989